Board of Directors
Sylvie Grégoire, Executive Chair
John Alam, CEO
Tatjana May
Tatjana May is non-executive member of the board of EIP Pharma. She is an experienced General Counsel with over 25 years of legal experience and substantial knowledge and understanding of the pharmaceutical sector. Between 2001 and 2015, Tatjana May was at Shire plc where she served as General Counsel and Company Secretary and was on Shire’s Executive Committee. She brings with her extensive legal and governance experience including working in a dual listed environment and managing M&A activity and litigation in both the EU and the USA. Prior to this Tatjana worked at AstraZeneca plc, where her last position was Assistant General Counsel. Tatjana graduated from Southampton University with a Bachelor of Laws, Tatjana’s early career was spent at Slaughter and May in London.
Tatjana is non-executive director at Indivior, a UK pharmaceutical company focused on finding therapies for the treatment of opioid addiction.
Jeff Poulton
Jeff Poulton is a non-executive member of the board of EIP Pharma. Jeff is Chief Financial officer at Indigo Agriculture, a plant microbiome company in Boston since January 2018. Before that, Jeff was at Shire plc, a biotechnology company, where he gained financial leadership experience from his role as Chief Financial Officer and member of Shire’s Executive Committee and Board of Directors. Prior to his CFO role at Shire he held a variety of financial roles and also gained general management experience while leading Shire’s rare disease US/APAC and LATAM commercial operations and leading Shire’s rare disease business unit. Prior to his fifteen-year tenure at Shire, Jeff led corporate finance and business development initiatives in both the energy (gas and electric utilities) industry and the materials manufacturing sector, acting in financial leadership positions at Cinergy Corp and PPG industries. He also has a military background, having served as a U.S. Navy Commissioned Officer aboard the USS Peoria. Jeff holds a B.A. in Economics from Duke University and an MBA in Finance from the Kelly School of Business at Indiana University.
Frank Zavrl
Frank Zavrl is a non-executive member of the board of EIP Pharma. Frank has substantial experience in investment in the pharma and biotechnology industry. From 2002 to 2011, he was a Partner at Adage Capital Management, L.P., specializing in biotechnology investments. Prior to joining Adage Capital, Frank was a Portfolio Manager from 1999 to 2002 at Merlin Biomed, a healthcare investment group. From 1998 to 1999, he was an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments. Frank received a B.S. in Biochemistry from the University of California, Berkeley and an M.B.A. from the Tuck School of Business at Dartmouth College.
Since 2015, Frank has been a member of the board of Puma Biotechnology, a company focused on the treatment of cancer.
Sylvie Grégoire, Executive Chair
John Alam, CEO
Tatjana May
Tatjana May is non-executive member of the board of EIP Pharma. She is an experienced General Counsel with over 25 years of legal experience and substantial knowledge and understanding of the pharmaceutical sector. Between 2001 and 2015, Tatjana May was at Shire plc where she served as General Counsel and Company Secretary and was on Shire’s Executive Committee. She brings with her extensive legal and governance experience including working in a dual listed environment and managing M&A activity and litigation in both the EU and the USA. Prior to this Tatjana worked at AstraZeneca plc, where her last position was Assistant General Counsel. Tatjana graduated from Southampton University with a Bachelor of Laws, Tatjana’s early career was spent at Slaughter and May in London.
Tatjana is non-executive director at Indivior, a UK pharmaceutical company focused on finding therapies for the treatment of opioid addiction.
Jeff Poulton
Jeff Poulton is a non-executive member of the board of EIP Pharma. Jeff is Chief Financial officer at Indigo Agriculture, a plant microbiome company in Boston since January 2018. Before that, Jeff was at Shire plc, a biotechnology company, where he gained financial leadership experience from his role as Chief Financial Officer and member of Shire’s Executive Committee and Board of Directors. Prior to his CFO role at Shire he held a variety of financial roles and also gained general management experience while leading Shire’s rare disease US/APAC and LATAM commercial operations and leading Shire’s rare disease business unit. Prior to his fifteen-year tenure at Shire, Jeff led corporate finance and business development initiatives in both the energy (gas and electric utilities) industry and the materials manufacturing sector, acting in financial leadership positions at Cinergy Corp and PPG industries. He also has a military background, having served as a U.S. Navy Commissioned Officer aboard the USS Peoria. Jeff holds a B.A. in Economics from Duke University and an MBA in Finance from the Kelly School of Business at Indiana University.
Frank Zavrl
Frank Zavrl is a non-executive member of the board of EIP Pharma. Frank has substantial experience in investment in the pharma and biotechnology industry. From 2002 to 2011, he was a Partner at Adage Capital Management, L.P., specializing in biotechnology investments. Prior to joining Adage Capital, Frank was a Portfolio Manager from 1999 to 2002 at Merlin Biomed, a healthcare investment group. From 1998 to 1999, he was an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments. Frank received a B.S. in Biochemistry from the University of California, Berkeley and an M.B.A. from the Tuck School of Business at Dartmouth College.
Since 2015, Frank has been a member of the board of Puma Biotechnology, a company focused on the treatment of cancer.
